Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)

被引：86

作者：

Yang, Yunpeng ^{[1
]}

Pan, Jianji ^{[2
]}

Wang, Hui ^{[3
]}

Zhao, Yuanyuan ^{[1
]}

Qu, Shenhong ^{[4
]}

Chen, Nianyong ^{[5
,6
]}

Chen, Xiaozhong ^{[7
]}

Sun, Yan ^{[8
]}

He, Xiaohui ^{[9
]}

Hu, Chaosu ^{[10
]}

Lin, Lizhu ^{[11
]}

Yu, Qitao ^{[12
]}

Wang, Siyang ^{[13
]}

Wang, Guihua ^{[14
]}

Lei, Feng ^{[15
]}

Wen, Jiyu ^{[16
]}

Yang, Kunyu ^{[17
]}

Lin, Zhixiong ^{[18
]}

Guo, Ye ^{[19
]}

Chen, Shaoqing ^{[20
]}

Huang, Xiaoming ^{[21
]}

Wu, Yanjie ^{[22
]}

Liang, Liang ^{[23
]}

Chen, Chenqi ^{[22
]}

Bai, Fan ^{[22
]}

Ma, Xiaopeng ^{[24
]}

Zhang, Yun ^{[23
]}

Leaw, Shiangjiin ^{[22
]}

Zhang, Li ^{[1
]}

Fang, Wenfeng ^{[1
]}

机构：

[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Med Oncol Sun Yat, State Key Lab Oncol South China,Canc Ctr,Guangdong, 16th Floor,2 Bldg,Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China

[2] Fujian Canc Hosp, Dept Head & Neck Radiat Oncol, 420 Fuma Rd, Fuzhou 350014, Fujian, Peoples R China

[3] Hunan Canc Hosp, Thorac Radiotherapy Dept 1, 283 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China

[4] Guangxi Acad Med Sci, Peoples Hosp Guangxi Zhuang Autonomous Reg, Canc Res Inst, Otolaryngol Dept, 6 Tao Yuan Rd, Nanning 530021, Guangxi, Peoples R China

[5] Sichuan Univ, West China Hosp, Canc Ctr, Dept Head & Neck Oncol, 37 Guoxuexiang, Chengdu 610041, Sichuan, Peoples R China

[6] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, 37 Guoxuexiang, Chengdu 610041, Sichuan, Peoples R China

[7] Zhejiang Canc Hosp, Dept Head & Neck Radiotherapy, 38 Guangji Rd, Hangzhou 310022, Zhejiang, Peoples R China

[8] Beijing Canc Hosp, Radiotherapy Dept, 52 Fucheng Rd, Beijing 100142, Peoples R China

[9] Chinese Acad Med Sci, Canc Hosp, Dept Med Oncol, 17 Panjiayuannanli, Beijing 100021, Peoples R China

[10] Fudan Univ, Shanghai Canc Ctr, Dept Radiat, 270 Dongan Rd, Shanghai 200032, Peoples R China

[11] Guangzhou Tradit Chinese Med Univ, Affiliated Hosp 1, Dept Oncol, 16 Airport Rd, Guangzhou 510405, Guangdong, Peoples R China

[12] Guangxi Med Univ, Affiliated Canc Hosp, Dept Med Oncol Resp, 71 Hedi Rd, Nanning 530021, Guangxi, Peoples R China

[13] Sun Yat Sen Univ, Affiliated Hosp 5, Head & Neck Oncol Sect 1, 52 Meihua East Rd, Zhuhai 519000, Peoples R China

[14] Changsha Cent Hosp, Dept Oncol, 161 Shaoshan South Rd, Changsha 410004, Hunan, Peoples R China

[15] Peoples Hosp Zhongshan City, Head & Neck Radiotherapy Dept, 2 Sunwen East Rd, Zhongshan 528403, Guangdong, Peoples R China

[16] Guangdong Med Univ, Affiliated Hosp, Canc Ctr, Nasopharyngeal Canc Dis Ctr, 57 South Renmin Rd, Zhanjiang 524000, Guangdong, Peoples R China

[17] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China

[18] Shantou Univ, Canc Hosp, Med Coll, Dept Radiat, 7 Raoping Rd, Shantou 515031, Guangdong, Peoples R China

[19] Tongji Univ, Shanghai East Hosp, Sch Med, Dept Oncol, 1800 Yuntai Rd, Shanghai 200123, Peoples R China

[20] Nanchang Univ, Affiliated Hosp 1, Dept Oncol, 17 Yongwaizheng St, Nanchang 330006, Jiangxi, Peoples R China

[21] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Otolaryngol Head & Neck Surg, 107 Yan Jiang West Rd, Guangzhou 510120, Guangdong, Peoples R China

[22] BeiGene Shanghai Co Ltd, Jing Kerry Ctr, Clin Dev, 20-F,Tower 3,1228 Middle Yanan Rd, Shanghai 200040, Peoples R China

[23] BeiGene Beijing Co Ltd, Clin Biomarker Sci & CDx Dev, 6 Jianguomenwai Ave,SK Tower,36th Floor, Beijing 100022, Peoples R China

[24] BeiGene Beijing Co Ltd, Bioinformat, 30 Sci Pk Rd,Zhongguancun Life Sci Pk, Beijing 102206, Peoples R China

来源：

CANCER CELL | 2023年 / 41卷 / 06期

关键词：

biomarker; clinical trial; double-blinded; gene expression profiling; immunotherapy; nasopharyngeal carcinoma; PD-1; inhibitor; randomized; tislelizumab;

D O I：

10.1016/j.ccell.2023.04.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Checkpoint inhibitors are effective in recurrent/metastatic nasopharyngeal cancer (R/M NPC). RATIONALE-309 (NCT03924986) randomized 263 treatment-naive R/M NPC patients to tislelizumab or placebo every 3 weeks (Q3W), plus chemotherapy (Q3W for 4-6 cycles). At interim analysis, progression-free survival (PFS) was significantly longer with tislelizumab-chemotherapy versus placebo -chemotherapy (hazard ratio: 0.52; 95% confidence interval: 0.38, 0.73; p < 0.0001). PFS benefit for tislelizumabchemotherapy versus placebo-chemotherapy was observed regardless of programmed death-ligand 1 expression. PFS after next line of treatment and overall survival showed favorable trends for tislelizumab-chemotherapy versus placebo-chemotherapy. The safety profile was similar between arms. Gene expression profiling (GEP) identified immunologically "hot"tumors, and showed an activated dendritic cell (DC) signature was associated with tislelizumab-chemotherapy PFS benefit. Our results support that tislelizumab-chemotherapy should be considered as first-line treatment for R/M NPC, and GEP and activated DC signature results may help identify patients who might benefit most from immunochemotherapy treatment.

引用

页码：1061 / +

页数：17

共 50 条

[41] Phase II trial of weekly docetaxel/gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer
O'Shaughnessy, Joyce A.
Pluenneke, Robert
Sternberg, Jack
Khandelwal, Pankaj
Ilegbodu, Des
Asmar, Lina
CLINICAL BREAST CANCER, 2006, 6 (06) : 505 - 510
[42] Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancer
Favier, Laure
Isambert, Nicolas
Zanetta, Sylvie
Ferrant, Ernmanuelle
Mayer, Francoise
Chauffert, Bruno
Fumoleau, Pierre
Garnier, Jerome
Biville, Fabienne
Coudert, Bruno
BREAST, 2008, 17 (01): : 36 - 41
[43] First-Line Chemotherapy With or Without Tislelizumab for Extensive-Stage Small Cell Lung Cancer: RATIONALE-312 Phase 3 Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (10) : 12 - 13
[44] Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China
Zhao, Ziying
Chen, Tongfeng
Zhou, Zhen
Guo, Rui
Liu, Qiao
BMJ OPEN, 2023, 13 (12):
[45] Updated Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Elderly Advanced NSCLC Patients
Shen, B.
Pan, B.
Wu, Y.
Shi, L.
Gao, J.
Du, X.
Feng, J.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S317 - S318
[46] Adoptive T-cell Transfer and Chemotherapy in the First-line Treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma
Chia, Whay-Kuang
Teo, Marissa
Wang, Who-Whong
Lee, Bernett
Ang, Soo-Fan
Tai, Wai-Meng
Chee, Chit-Lai
Ng, Joanna
Kan, Rebecca
Lim, Wan-Teck
Tan, Sze-Huey
Ong, Whee-Sze
Cheung, Yin-Bun
Tan, Eng-Huat
Connolly, John E.
Gottschalk, Stephen
Toh, Han-Chong
MOLECULAR THERAPY, 2014, 22 (01) : 132 - 139
[47] First-Line Chemotherapy With or Without Tislelizumab for Extensive-Stage Small Cell Lung Cancer: RATIONALE-312 Phase 3 Study
Cheng, Y.
Fan, Y.
Zhao, Y.
Huang, D.
Li, X.
Zhang, P.
Kang, M.
Yang, N.
Zhong, D.
Wang, Z.
Yu, Y.
Zhang, Y.
Zhao, J.
Qin, T.
Chen, C.
Leaw, S.
Zheng, W.
Song, Y.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S46 - S46
[48] Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma
Chen, Chen
Zhou, Yixin
Zhang, Xuanye
Fu, Sha
Lin, Zuan
Fang, Wenfeng
Yang, Yunpeng
Huang, Yan
Zhao, Hongyun
Hong, Shaodong
Zhang, Li
CANCER MEDICINE, 2020, 9 (05): : 1721 - 1732
[49] Outcomes of Radiotherapy in the First-Line Treatment of Recurrent/Metastatic Cervical Cancer: A Multicenter, Retrospective Study
Peng, C.
Li, X.
Tang, W.
Guo, Q.
Wu, Q.
Xie, P.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : S189 - S189
[50] Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II Trial
Assenat, Eric
Desseigne, Francoise
Thezenas, Simon
Viret, Frederic
Mineur, Laurent
Kramar, Andrew
Samalin, Emmanuelle
Portales, Fabienne
Bibeau, Frederic
Crapez-Lopez, Evelyne
Bleuse, Jean Pierre
Ychou, Marc
ONCOLOGIST, 2011, 16 (11): : 1557 - 1564

← 1 2 3 4 5 →